Oncomine Comprehensive Panel and Oncomine Tumor Mutation Burden TMB and MSI and PD-L1 Test sale cost 24000 AED
Clinical Exome Trio Sequencing Test sale cost 12000 AED Clinical Exome Trio Sequencing Test 15,000 د.إ 12,000 د.إ
Sale!

Oncomine Comprehensive Panel and Oncomine Tumor Mutation Burden TMB and MSI and PD-L1 Test

24,000 د.إ

-25%

The Oncomine Comprehensive Panel, along with the Oncomine Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), and PD-L1 Test, is an advanced genetic testing suite designed for a comprehensive analysis of cancer genomes. Offered by DNA Labs in the UAE, this suite of tests provides a detailed overview of the genetic alterations in tumors, aiding in the personalized treatment of cancer patients.

The Oncomine Comprehensive Panel is a next-generation sequencing (NGS) test that identifies DNA and RNA changes across a wide array of cancer-related genes. This broad-spectrum analysis helps in understanding the molecular underpinnings of an individual’s cancer, facilitating targeted therapy decisions.

The Oncomine TMB test quantifies the total number of mutations within a tumor genome, providing an index of the tumor’s mutation burden. A high TMB is often associated with better responses to immunotherapies, making this test crucial for therapy selection.

The MSI test assesses the status of microsatellite instability in cancer cells, which is a condition of genetic hypermutability that results from the impairment of DNA mismatch repair. MSI status is a key biomarker in certain types of cancers, such as colorectal cancer, and influences treatment choices.

The PD-L1 test measures the expression of the PD-L1 protein on the surface of tumor cells. PD-L1 is a checkpoint protein that helps cancers evade the immune system. Knowing the PD-L1 status can guide the use of checkpoint inhibitor therapies, which can be effective in treating various types of cancer.

Conducted at DNA Labs in the UAE, the comprehensive suite of these tests is priced at 24,000 AED. This investment in precision medicine can significantly impact treatment strategies, offering hope for better outcomes by tailoring therapies to the specific genetic profile of a patient’s tumor.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Oncomine Comprehensive Panel and Oncomine Tumor Mutation Burden (TMB) and MSI and PDL1 Test

Test Name: Oncomine Comprehensive Panel and Oncomine Tumor Mutation Burden (TMB) and MSI and PDL1 Test

Components: Paraffin embedded tissue blocks + EDTA Vacutainer (3 ml)

Price: 24000.0 AED

Sample Condition: Tumor tissue + Peripheral Blood

Report Delivery: 2-3 weeks

Method: NGS, Sanger Sequencing, IHC

Test type: Genetics

Doctor: Oncology

Test Department:

Pre Test Information: Oncomine Comprehensive Panel + Oncomine Tumor Mutation Burden (TMB) + MSI + PDL1 can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details:

Oncomine Comprehensive Panel is a next-generation sequencing (NGS) assay that targets over 500 cancer-related genes, including known oncogenes and tumor suppressor genes. This panel can detect somatic mutations, copy number alterations, and gene fusions across various cancer types.

Oncomine Tumor Mutation Burden (TMB) is a measure of the number of mutations in the DNA of a tumor cell. High TMB has been associated with improved response to immunotherapy in some cancer types.

Microsatellite instability (MSI) is a genomic marker that reflects defects in DNA mismatch repair (MMR) pathways. MSI-high tumors have been shown to be more responsive to immunotherapy.

Programmed death-ligand 1 (PD-L1) is a protein that is expressed on the surface of some cancer cells and can interact with immune cells to suppress the immune response. PD-L1 expression has been used as a biomarker to predict response to immunotherapy.

Combining these assays can provide a comprehensive picture of the genomic landscape of a patient’s tumor, including potential biomarkers for immunotherapy response.

Test Name Oncomine Comprehensive Panel and Oncomine Tumor mutation burden TMBand MSI and PDL1 Test
Components Paraffin embedded tissue blocks + EDTA Vacutainer (3 ml)
Price 24000.0 AED
Sample Condition Tumor tissue + Peripheral Blood
Report Delivery 2-3 weeks
Method NGS, Sanger Sequencing, IHC
Test type Genetics
Doctor Oncology
Test Department:
Pre Test Information Oncomine Comprehensive Panel + Oncomine Tumor mutation burden (TMB)+ MSI + PDL1 can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

Oncomine Comprehensive Panel is a next-generation sequencing (NGS) assay that targets over 500 cancer-related genes, including known oncogenes and tumor suppressor genes. This panel can detect somatic mutations, copy number alterations, and gene fusions across various cancer types.

Oncomine Tumor Mutation Burden (TMB) is a measure of the number of mutations in the DNA of a tumor cell. High TMB has been associated with improved response to immunotherapy in some cancer types.

Microsatellite instability (MSI) is a genomic marker that reflects defects in DNA mismatch repair (MMR) pathways. MSI-high tumors have been shown to be more responsive to immunotherapy.

Programmed death-ligand 1 (PD-L1) is a protein that is expressed on the surface of some cancer cells and can interact with immune cells to suppress the immune response. PD-L1 expression has been used as a biomarker to predict response to immunotherapy.

Combining these assays can provide a comprehensive picture of the genomic landscape of a patient’s tumor, including potential biomarkers for immunotherapy response.

SKU: TEST-672 Category:

Related products